Close menu




March 14th, 2022 | 12:47 CET

BioNTech, Defence Therapeutics, MorphoSys - Shares with blockbuster potential!

  • Biotechnology
Photo credits: pixabay.com

Developing a blockbuster drug is the highest achievement in the pharmaceutical industry. A blockbuster is defined as a drug that can generate more than USD 1 billion in revenues per year. According to experts, the vaccine Comirnaty, developed by BioNTech and Pfizer, is likely to have brought in sales of well over USD 30 billion, thus clearly breaking the blockbuster barrier. Outside of vaccine research, there are also numerous companies with high long-term potential.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , DEFENCE THERAPEUTICS INC | CA24463V1013 , MORPHOSYS AG O.N. | DE0006632003

Table of contents:


    Defence Therapeutics - Comprehensive pipeline

    Canadian company Defence Therapeutics is undoubtedly uniquely positioned with its patented Accum technology. It has blockbuster potential in the long term, but the road to a finished drug is still long.

    Defence Therapeutics' business is divided into two segments. The first segment is immuno-oncology, the second is research into infectious diseases. Here, the young Company is researching vaccines against breast and skin cancer and is pursuing an innovative therapeutic approach in tumor therapy with the antibody-drug conjugate (ADC). In the area of infectious diseases, Defence Therapeutics is researching vaccines against COVID-19 and the human papillomavirus (HPV).

    At the end of 2022 or the beginning of 2023, a phase I study is to start activities against breast and skin cancer. Until then, the necessary preliminary work will be carried out according to the principles of Good Laboratory Practice (GLP). Further data will be collected that will be useful for further approval.

    Recently, the first peer-reviewed efficacy study of AccuVAC-D001L was announced and published in the prestigious journal Cell Reports Medicine. Currently, only one FDA-approved DC vaccine is on the market to treat prostate cancer. However, the vaccine did not achieve the hoped-for clinical effect due to major obstacles related to antigen presentation by dendritic cells (DCs) versus responding T cells. This is where AccumTM technology proves to be an important advantage, as it allows circumventing the main enemy of any antigen, i.e. entrapment in the endosome.

    The market capitalization of the Canadians is currently CAD 145 million. In an in-depth interview, Dr. Moutih Rafei, director and VP of R&D at Defence Therapeutics, highlights the strengths of Accum's platform technology.

    MorphoSys - High depreciation

    The MorphoSys share price knew only one direction last year, down. While the share was still quoted at prices above EUR 100 in 2021, it can currently be bought for EUR 23.60 per share. Last week, the Martinsried-based biotechnology company announced that it would have to take write-downs of around EUR 231 million. These write-downs are necessary following the acquisition of the US cancer specialist Constellation Pharmaceuticals. The write-downs are not cash-effective, but they will negatively impact the Group's operating result in the amount of EUR 231 million.

    Despite the somewhat negative news, the share price reacted with gains. On March 16, the biotech group plans to publish its financial statements for the past fiscal year. After the high write-down on the US acquisition Constellation, Deutsche Bank left its rating for MorphoSys at "Hold", the price target was confirmed at EUR 46. The Company is currently valued at around EUR 800 million.

    BioNTech - At important support

    Vaccine producer BioNTech has also seen a sell-off in recent weeks, with the share price plummeting from USD 464.00 to currently USD 135.64 in recent months. The area around USD 131 is important here. Should this be broken, the next striking support area would be found at USD 105.

    The three founders of the pharmaceutical Company BioNTech had something to celebrate. Ugur Sahin, Özlem Türeci and Christoph Huber were appointed honorary citizens by the city of Mainz. In doing so, Mainz wants to honor the "outstanding achievements of these exceptional scientists in the field of medical research and biotechnology." Operationally, BioNTech continues to expand its partnership with the US biotech company Regeneron to develop cancer therapies. The two partners are planning a joint clinical trial of BioNTech's cancer vaccine BNT116 in combination with Regeneron's cancer drug Libtayo to treat patients with advanced non-small cell lung cancer.


    BioNTech was able to launch a blockbuster with its Comirnaty vaccine. Defence Therapeutics also has the potential to generate annual sales in the billions with its Accum platform. At MorphoSys, on the other hand, there is a need for write-downs.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Stefan Feulner on September 27th, 2022 | 11:45 CEST

    Evotec, Defence Therapeutics, Formycon - Biotech opportunity!

    • Biotechnology

    Due to the stricter monetary policy of the central banks and inflation concerns, the capital-intensive biotech sector is also suffering. The NASDAQ Biotechnology Index has lost almost a quarter of its value since the beginning of the stock market year. In addition, the number of companies trading even below their cash levels is higher than ever. At the same time, as can be seen with vaccine manufacturers, the industry is becoming increasingly important in everyday life. Especially in cancer research, some companies have the opportunity to multiply in the coming years based on their product pipeline.

    Read